PEGylation of bacteriophages increases blood circulation time and reduces T‐helper type 1 immune response
Open accessThe DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
Summary: The increasing occurrence of antibiotic‐resistant pathogens is of growing concern, and must be counteracted by alternative antimicrobial treatments. Bacteriophages represent the natural enemies of bacteria. However, the strong immune response following application of phages and rapid clearance from the blood stream are hurdles which need to be overcome. Towards our goal to render phages less immunogenic and prolong blood circulation time, we have chemically modified intact bacteriophages by conjugation of the non‐immunogenic polymer monomethoxy‐polyethylene glycol (mPEG) to virus proteins. As a proof of concept, we have used two different polyvalent and strictly virulent phages of the Myoviridae , representing typical candidates for therapeutical approaches: Felix‐O1 (infects Salmonella ) and A511 (infects Listeria ). Loss of phage infectivity after PEGylation was found to be proportional to the degree of modification, and could be conveniently controlled by adjusting the PEG concentration. When injected into naïve mice, PEGylated phages showed a strong increase in circulation half‐life, whereas challenge of immunized mice did not reveal a significant difference. Our results suggest that the prolonged half‐life is due to decreased susceptibility to innate immunity as well as avoidance of cellular defence mechanisms. PEGylated viruses elicited significantly reduced levels of T‐helper type 1‐associated cytokine release (IFN‐γ and IL‐6), in both naïve and immunized mice. This is the first study demonstrating that PEGylation can increases survival of infective phage by delaying immune responses, and indicates that this approach can increase efficacy of bacteriophage therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PEG conjugation moderately protects adeno‐associated viral vectors against antibody neutralization
Lee, G. K., Maheshri, N., Kaspar, B., & Schaffer, D. V. (2005) · Biotechnology and Bioengineering · doi:10.1002/bit.20562 · Cited by 169 · cited 1×
“…and cellular immune responses in innate (Croyle et al., 2004; Mok et al., 2004) as well as in adaptive immunity (Croyle et al., 2001; 2002; 2005; Lee et al., 2005), protection from neutralizing antibody in vitro (O’Riordan et al., 1999; Croyle et al., 2000), improved virus stability (Croyle et…”
Background
Cited by
Phage Therapy in the Postantibiotic Era
Gordillo Altamirano, F. L., & Barr, J. J. (2019) · Clinical Microbiology Reviews · doi:10.1128/cmr.00066-18 · Cited by 1,180
Bacteriophage Endolysins as Novel Antimicrobials
Schmelcher, M., Donovan, D. M., & Loessner, M. J. (2012) · Future Microbiology · doi:10.2217/fmb.12.97 · Cited by 785
Self-citationDąbrowska, K. (2019) · Medicinal Research Reviews · doi:10.1002/med.21572 · Cited by 375
The next generation of bacteriophage therapy
Lu, T. K., & Koeris, M. S. (2011) · Current Opinion in Microbiology · doi:10.1016/j.mib.2011.07.028 · Cited by 312
Revisiting phage therapy: new applications for old resources
Nobrega, F. L., Costa, A. R., Kluskens, L. D., & Azeredo, J. (2015) · Trends in Microbiology · doi:10.1016/j.tim.2015.01.006 · Cited by 310
Metadata
- Authors
- Kim, K., Cha, J., Jang, E., Klumpp, J., Hagens, S., Hardt, W., Lee, K., & Loessner, M. J.
- Venue
- Microbial Biotechnology
- Publisher
- Wiley
- Published
- 2008-03-10
- Volume
- 1
- Issue
- 3
- Pages
- 247-257
- ISSN
- 1751-7915 (ISSN-L)
- OpenAlex
- W1989635094
- Cited by
- 128
- References
- 1
- FWCI
- 1.69
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: PEGylation of bacteriophages increases blood circulation time and reduces T‐helper type 1 immune response. https://app.cochat.ai/papers/10.1111/j.1751-7915.2008.00028.x
- The paper
- Kim, K., Cha, J., Jang, E., Klumpp, J., Hagens, S., Hardt, W., Lee, K., & Loessner, M. J. (2008). PEGylation of bacteriophages increases blood circulation time and reduces T‐helper type 1 immune response. Microbial Biotechnology. https://doi.org/10.1111/j.1751-7915.2008.00028.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.